Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. [electronic resource]
Producer: 20040123Description: 2392-400 p. digitalISSN:- 0887-6924
- Adult
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Benzamides
- Cross-Over Studies
- Cytarabine -- administration & dosage
- Cytogenetics
- Female
- Fusion Proteins, bcr-abl -- genetics
- Humans
- Imatinib Mesylate
- Interferon-alpha -- administration & dosage
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- diagnosis
- Male
- Middle Aged
- Piperazines -- administration & dosage
- Prognosis
- Prospective Studies
- Pyrimidines -- administration & dosage
- RNA, Messenger -- metabolism
- Recurrence
- Risk Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.